Molecularly Targeted Therapy for Osteosarcoma: Where Do We Go from Here?

  • Rosanna Ricafort
  • Richard Gorlick


Osteosarcoma at the molecular level is among the most complex pediatric ­malignancies. Despite its relatively high incidence in the pediatric patient population many aspects of this disease continue to defy understanding. Osteosarcoma is the most common primary malignant bone tumor in children and adolescents (Arndt and Crist 1999). Approximately 400 children and adolescents are diagnosed each year in the United States (Meyers and Gorlick 1997). In the adolescent age range, it is the second most common malignancy, following only lymphoma in incidence. Osteosarcoma continues to be diagnosed solely based upon its histologic appearance. Despite having tremendously variable appearance, characterized descriptively by its histologic subtype, the presence of a malignant spindle cell which produces osteoid is the basis for diagnosing osteosarcoma. Molecular analyses of gene copy number, translocations, and gene expression do not contribute to making the diagnosis.


Werner Syndrome Ezrin Expression Bloom Syndrome Cancer Predisposition Syndrome Familial Cancer Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahuja D, Sáenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 24:7729–45.PubMedCrossRefGoogle Scholar
  2. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. 1998. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 250:229–34.PubMedCrossRefGoogle Scholar
  3. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, et al. 2002. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397–404.PubMedCrossRefGoogle Scholar
  4. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. 2004. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31:53–90.PubMedCrossRefGoogle Scholar
  5. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, et al. 1999. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 5:2316–23.PubMedGoogle Scholar
  6. Anderson PM, Pearson M. 2006. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 8:310–5.PubMedCrossRefGoogle Scholar
  7. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, et al. 2002. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20:189–96.PubMedCrossRefGoogle Scholar
  8. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, et al. 2005. Gemcitabine radiosensitization after high-dose samarium for osteblastic osteosarcoma. Cin Cancer Res 11:6895–6900.Google Scholar
  9. Anninga JK, van der Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW. 2004. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40:963–970.PubMedCrossRefGoogle Scholar
  10. Arndt CA, Crist WM. 1999. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–52.PubMedCrossRefGoogle Scholar
  11. Ashton JA, Farese JP, Milner RJ, Lee-Ambrose LM, van Gilder JM. 2005. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 66:885–91.PubMedCrossRefGoogle Scholar
  12. Aue G, Muralidhar B, Schwartz HS, Butler MG. 1998. Telomerase activity in skeletal sarcomas. Ann Surg Oncol 5:627–634.PubMedCrossRefGoogle Scholar
  13. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. 2000. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016–27.PubMedGoogle Scholar
  14. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. 2005. Hsp90 inhibitors deplete key antiapoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 113:179–88.PubMedCrossRefGoogle Scholar
  15. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, et al. 2007. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783–8.PubMedCrossRefGoogle Scholar
  16. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. 1995. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380–1385.PubMedCrossRefGoogle Scholar
  17. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, et al. 1995. Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol. 42:457–64.PubMedGoogle Scholar
  18. Baselga J, Norton L, Albanell J, Young-Mee K, Medelsohn J. 1998. Recombinant humanized anti-HER-2 antibody (HERceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831.PubMedGoogle Scholar
  19. Baserga R, Peruzzi F, Reiss K. 2003. The IGF-1 receptor in cancer biology. Int J Cancer 107:873–877.PubMedCrossRefGoogle Scholar
  20. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K et al. 2003. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36:7–16.PubMedCrossRefGoogle Scholar
  21. Bech-Otschir, Kraft R, Huan X, Henklein P, Kapelari B, Pollmann C, Dubiel W. 2001. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630–1639.PubMedCrossRefGoogle Scholar
  22. Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, et al. 1999. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 84:489–93.PubMedCrossRefGoogle Scholar
  23. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, et al. 1999. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer. 80:581–8.PubMedCrossRefGoogle Scholar
  24. Bertoni F, Present D, Bacchini P, Pignatti G, Picci P, Campanacci M. 1989. The Istituto Rizzoli experience with small cell osteosarcoma. Cancer 64:2591–9.PubMedCrossRefGoogle Scholar
  25. Betino JR. 1993. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11:5–14.Google Scholar
  26. Bjornsti MA, Houghton PJ. 2004. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–48.PubMedCrossRefGoogle Scholar
  27. Bleul CC, Fuhlbrigge RC, Cassnovas JM, Aiuti A, Springer TA. 1996. A highly efficacious lymphocyte cheomattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101–1109.PubMedCrossRefGoogle Scholar
  28. Bode AM, Dong Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.PubMedCrossRefGoogle Scholar
  29. Boland GM, Perkins G, Hall DJ, Tuan RS. 2004. Wnt3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210–1230.PubMedCrossRefGoogle Scholar
  30. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC. 2008. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 50:254–258.PubMedCrossRefGoogle Scholar
  31. Bostedt KT, Schmid C, Ghirlanda-Keller C, Ollie R, Winterhalter KH, Zapf J. 2001. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 271:368–377.PubMedCrossRefGoogle Scholar
  32. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145.PubMedGoogle Scholar
  33. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. 1995. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 92:2558–2562.PubMedCrossRefGoogle Scholar
  34. Burrow S, Andrulis IL, Pollak M, Bell RS. 1998. Expression of insulin-like growth factor receptor­, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69:21–7.PubMedCrossRefGoogle Scholar
  35. Carbone M, Rizzo P, Procopio A, Giuliano M, Pass HI, Gebhardt MC, Mangham C, Hansen M, Malkin DF, Bushart G, Pompetti F, Picci P, Levine AS, Bergsagel JD, Garcea RL. 1996. SV40-like sequences in human bone tumors. Oncogene 13:527–535.PubMedGoogle Scholar
  36. Carli M, Passone E, Perilongo G, Bisogno G. 2003. Ifosfamide in pediatric solid tumors. Oncology 65 Suppl 2:99–104.PubMedCrossRefGoogle Scholar
  37. Carpio L, Gladu J, Goltzman D, Rabbani SA. 2001. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Phsyiol Endocrinol Metab. 281:E489–E499.Google Scholar
  38. Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA. 2003. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst. 95:1522–30.PubMedCrossRefGoogle Scholar
  39. Casas-Ganem J, Healey JH. 2005. Advances that are changing the diagnosis and treatment of malignant bone tumors. Curr Opin Rheumatol. 17:79–85.PubMedCrossRefGoogle Scholar
  40. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. 1997. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706–1715.PubMedCrossRefGoogle Scholar
  41. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. 2006. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 448:193–8.PubMedCrossRefGoogle Scholar
  42. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. 2004. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 42:410–5.PubMedCrossRefGoogle Scholar
  43. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, et al. 2000. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs. 18:253–9.PubMedCrossRefGoogle Scholar
  44. Chou A, Merola P, Sowers R, Yang R, Kolb E, Healey J, et al. 2005a. Analysis of Aberrant signal transduction pathways in osteosarcoma cell lines. Proc Am Assoc Cancer Res 46: Abstract #4551, 1075.Google Scholar
  45. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, et al. 2005b. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104:2214–21.PubMedCrossRefGoogle Scholar
  46. Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, Gorlick R. 2007. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 25:18S; Abstract #9525.Google Scholar
  47. Chou AJ, Gorlick R. 2006. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 6:1075–85.PubMedCrossRefGoogle Scholar
  48. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910–7.PubMedCrossRefGoogle Scholar
  49. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. 2005. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063–2073.PubMedCrossRefGoogle Scholar
  50. Corcione A, Ottonello L, Tortolina G, Facchetti P, Airoldi I, Guglielmino R, Dadati P, Truini M, Sozzani S, Dallegri F, Pistoia V. 2000. Stomal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst 92:628–635.PubMedCrossRefGoogle Scholar
  51. Cowley S, Paterson H, Kemp P, Marshall CJ. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:841–52PubMedCrossRefGoogle Scholar
  52. Curran T, MacConnell WP, van Straaten F, Verma IM. 1983. Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol. 3:914–21PubMedGoogle Scholar
  53. David JP, Mehic D, Bakiri L, Schilling AF, Mandic V, Priemel M, et al. 2005. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 115:664–72.PubMedGoogle Scholar
  54. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949–54.PubMedCrossRefGoogle Scholar
  55. Davis AM, Bell RS, Goodwin PJ. 1994. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 12:423–31.PubMedGoogle Scholar
  56. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. 2005a. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 61:492–8.PubMedCrossRefGoogle Scholar
  57. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. 2005b. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 12:27–35.PubMedGoogle Scholar
  58. Diel IJ, Solomayer EF, Bastert G. 2000. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88:3080–3088.PubMedCrossRefGoogle Scholar
  59. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–21.PubMedCrossRefGoogle Scholar
  60. Draper GJ, Sanders BM, Kingston JE. 1986. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661–671.PubMedCrossRefGoogle Scholar
  61. Druker BJ, Tamura S, Buchdunger E, Ohno S, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566.PubMedCrossRefGoogle Scholar
  62. DuBois S, Demetri G. 2007. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 109:813–9.PubMedCrossRefGoogle Scholar
  63. Easton JB, Houghton PJ. 2006. mTOR and cancer therapy. Oncogene 25:6436–46.PubMedCrossRefGoogle Scholar
  64. El-Diery WS. 1998. Regulation of p53 downstream genes. Sem Cancer Biol 8:345–57.CrossRefGoogle Scholar
  65. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, et al. 1995. The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell 83:655–666.PubMedCrossRefGoogle Scholar
  66. Erfle V, Schmidt J, Strauss GP, Hehlmann R, Luz A. 1986. Activation and biological properties of endogenous retroviruses in radiation osteosarcomagenesis. Leuk Res 10:905–13.PubMedCrossRefGoogle Scholar
  67. Ferracini R, Renzo MFD, Scotlandi K, et al. 1995. The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or autocrine circuit. Oncogene 10:739–49.PubMedGoogle Scholar
  68. Feugas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S et al. 1996. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14:467–472.Google Scholar
  69. Finkel MP, Biskis BO, Jinkins PB. 1966. Virus induction of osteosarcomas in mice. Science 151:698–701.PubMedCrossRefGoogle Scholar
  70. Franchi A, Calzolari A, Zampi G. 1998. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 432:515–519.PubMedCrossRefGoogle Scholar
  71. Fukaya Y, Ishiguro N, Senga T, Ichigotani Y, Sohara Y, Tsutsui M, Shioura T, Iwamoto T, Hamaguchi M. 2005. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep.14:847–52.PubMedGoogle Scholar
  72. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Solazzo MR, et al. 1998. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55:556–563.PubMedCrossRefGoogle Scholar
  73. Gelberg KH, Fitzgerald EF, Hwang S, Dubrow R. 1997. Growth and development and other risk factors for osteosarcoma in children and young adults Int J Epidemiol. 26:272–278.PubMedCrossRefGoogle Scholar
  74. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. 2005. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967–76.PubMedCrossRefGoogle Scholar
  75. Goetsch L, Gonzalez A, Leger O, et al. 2005. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–328PubMedCrossRefGoogle Scholar
  76. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. 1996. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 11:5–14.Google Scholar
  77. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. 1999. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 17:2781–8.PubMedGoogle Scholar
  78. Gorlick R, Meyers PA. 2003a. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 25:840–1.PubMedCrossRefGoogle Scholar
  79. Gorlick R, Anderson P, Andrulis I, Arndt C, et al. 2003b. Biology of childhood osteogenic ­sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 9:5442–5453.PubMedGoogle Scholar
  80. Goto M, Miller RW, Ishikawa Y, Sugano H. 1996. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5:239–246.PubMedGoogle Scholar
  81. Grigoriadis AE, Schellander K, Wang ZW, Wagner ER. 1993. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122:685–701.PubMedCrossRefGoogle Scholar
  82. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, et al. 1999. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 5:621–627.PubMedGoogle Scholar
  83. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. 1998. Chemokine receptor in human endothelial cells. Functional expression of CXCR4 and its transctiptional regulation by inflammatory cytokines. J Biol Chem. 273:4282–4287.PubMedCrossRefGoogle Scholar
  84. Hailey J, Maxwell E, Koukouras K, Bishop WR, Patcher JA, Wang Y. 2002. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther. 1:1349–1353.PubMedGoogle Scholar
  85. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. 2006. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 66:362–371.PubMedCrossRefGoogle Scholar
  86. Hanahan D and Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57–70.PubMedCrossRefGoogle Scholar
  87. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. 1991. A monoclonal antibody against the c-erbB-2 signaling enhances the cytotoxity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575–4580.PubMedGoogle Scholar
  88. Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, et al. 1985. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci 82:6216–6220.PubMedCrossRefGoogle Scholar
  89. Haydon RX, Deyrup A, Ishikawa A, Heck R, et al. 2002a. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102:338–342.PubMedCrossRefGoogle Scholar
  90. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jian W, et al. 2002b. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8:1288–1294.PubMedGoogle Scholar
  91. Haydon RC, Luu HH, He TC. 2007. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 454:237–246.PubMedCrossRefGoogle Scholar
  92. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, and Oberg K. 1993. Expression and prognostic significance of platelet-derived growth factor and its receoptors in epithelial ovarian neoplasms. Cancer Res. 53:4550–4554.PubMedGoogle Scholar
  93. Henriksen J, Aagesen TH, Maelsandsmo GM, Lothe RA, Myklebost O, Forus A. 2003. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358–5361.PubMedCrossRefGoogle Scholar
  94. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza BA, Yang R, Huvos AG, Meyers PA, Gorlick R. 2004a. Expression of LDL receptor-related protein (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106–111.PubMedCrossRefGoogle Scholar
  95. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza BA, Meyers PA, Gorlick R. 2004b. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res. 64:2734–2739.PubMedCrossRefGoogle Scholar
  96. Hornicek FJ, Gebhardt MC, Wolfe MW, Kharrazi FD, Takashita H, Parekh SG, et al. 2000. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res. 373:11–17.PubMedCrossRefGoogle Scholar
  97. Houghton PJ, Maris JM, Friedman HS, Keir ST, Lock RB, Carol H, et al. 2007a. Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sunitinib. In: American Association for Cancer Research Annual Meeting: Proceedings. Abstract #527.Google Scholar
  98. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. 2007b. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799–805.CrossRefGoogle Scholar
  99. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, et al. 2008. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50:37–45.PubMedCrossRefGoogle Scholar
  100. Hudis C. 2007. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357: 39–51.PubMedCrossRefGoogle Scholar
  101. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. 2004. Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of her-4 in primary osteosarcoma. Cancer Res. 64:2047–2053.PubMedCrossRefGoogle Scholar
  102. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. 2006. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46:614–23.PubMedCrossRefGoogle Scholar
  103. Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, et al. 1989. Amplification of both c-myc and c-raf oncogenes in a human osteosarcoma. Jpn J Cancer Res 80:6–9.PubMedCrossRefGoogle Scholar
  104. Itoh Y, Tamai M, Yokogawa K, Nomura M, Moritani S, Suzuki H, et al. 2002. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 22:1649–53.PubMedGoogle Scholar
  105. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. 2003. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20:525–529.PubMedCrossRefGoogle Scholar
  106. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4:1–7.PubMedCrossRefGoogle Scholar
  107. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102–4.PubMedCrossRefGoogle Scholar
  108. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. 2001. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870–7.PubMedCrossRefGoogle Scholar
  109. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. 2005. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics 28:755–760.PubMedGoogle Scholar
  110. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827.PubMedCrossRefGoogle Scholar
  111. Kappel CC, Velez-Yanguas MC, Hirschfeld S, and Helman LJ. 1994. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54:2803–2807.PubMedGoogle Scholar
  112. Kawai T, Hiroi S, Torikata C. 1997. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77:431–436.PubMedGoogle Scholar
  113. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572–7.PubMedGoogle Scholar
  114. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, et al. 2002. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 6:864–9.CrossRefGoogle Scholar
  115. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. 2005. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559–68.PubMedCrossRefGoogle Scholar
  116. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. 2000. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 18:261–271.PubMedCrossRefGoogle Scholar
  117. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, et al. 2001. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750–3759.PubMedGoogle Scholar
  118. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, et al. 2002. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor ­suppression and chemotherapy. Clin Cancer Res 8:2406–12.PubMedGoogle Scholar
  119. Khanna C, Wan X, Bose S, et al. 2004. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182–186.PubMedCrossRefGoogle Scholar
  120. Khidr L, Chen PL. 2006. RB, the conductor that orchestrates life, death and differentiation. Oncogene 25:5210–5219.PubMedCrossRefGoogle Scholar
  121. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, Bos GD. 2001. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14:1277–1283.PubMedCrossRefGoogle Scholar
  122. Kleinerman ES. 1995. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 9:927–38.PubMedGoogle Scholar
  123. Kloen P, Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, Gold LI, Makin HJ. 1997. Expression of transforming growth factor-beta isoforms in osteosarcomas: TGF-β3 is related to disease progression. Cancer 80:2230–2239.PubMedCrossRefGoogle Scholar
  124. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. 2008. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1190–1197.PubMedCrossRefGoogle Scholar
  125. Knowles BB, McCarrick J, Fox N, Solter D, Damjanov I. 1990. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol.137:259–62.PubMedGoogle Scholar
  126. Kochevar DT, Kochevar J, Garrett L. 1990. Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett. 53:213–22.PubMedCrossRefGoogle Scholar
  127. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. 2006. Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 23:227–36.PubMedCrossRefGoogle Scholar
  128. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by MDM2. Nature 387:299–303.PubMedCrossRefGoogle Scholar
  129. Kubo T, Gorlick R, Meyers P, Sowers R, et al. 2002. Expression and potential role of platelet-derived growth factor receptor and c-Kit in relation to the antiproliferative effect of ST1571 in osteosarcoma. Proc Am Assoc Cancer Res 43:846.Google Scholar
  130. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJS, Martin RJ, Gillespie MT, Onyia JE. 2005. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 95:1178–1190.PubMedCrossRefGoogle Scholar
  131. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. 1993a. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16–8.PubMedGoogle Scholar
  132. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. 1993b. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2:63–167.Google Scholar
  133. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, et al. 2003. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832–40.PubMedCrossRefGoogle Scholar
  134. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. 2005. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 11:2561–7.PubMedCrossRefGoogle Scholar
  135. Lawrence TS, Eishbruch A, McGinn CJ, Fields MT, Shewach DS. 1999. Radiosensitization by gemcitabine. Oncology 13:55–60.PubMedGoogle Scholar
  136. Lee J, Hoang B, Chou A, Meyers P, Healey J, Gorlick R. 2007. Expression of vascular endothelial growth factor correlates with chemotherapy response in osteosarcoma patients. Am Assoc Cancer Res Annu Meet: Proc. #3489. 48:830.Google Scholar
  137. Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, et al. 2007. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97:1552–1559.PubMedCrossRefGoogle Scholar
  138. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, et al. 1999. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35:1089–93.PubMedCrossRefGoogle Scholar
  139. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362.PubMedGoogle Scholar
  140. Libura J, Drukala J, Majka M, Dreyfus MG, Tucker MA, Miller RW. 2002. CXCR4-SDF-1 signaling­ is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100:2597–2606.PubMedCrossRefGoogle Scholar
  141. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA. 97:4174–9.PubMedCrossRefGoogle Scholar
  142. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. 2008. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1181–9.PubMedCrossRefGoogle Scholar
  143. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. 1997. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79:1541–47.PubMedCrossRefGoogle Scholar
  144. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE. 1989. Therapy of osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935–936.PubMedCrossRefGoogle Scholar
  145. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, et al. 2004. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77–91.PubMedCrossRefGoogle Scholar
  146. Maitra A, Wanzer D, Weinber AG, Ashfaq R. 2001. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92:677–83.PubMedCrossRefGoogle Scholar
  147. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, et al. 1990. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.PubMedCrossRefGoogle Scholar
  148. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC, Rao PH. 2004. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer. 4:45.PubMedCrossRefGoogle Scholar
  149. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, et al. 2002. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 24:440–6.PubMedCrossRefGoogle Scholar
  150. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase 1994. Science 265(5174):966–70.PubMedCrossRefGoogle Scholar
  151. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, et al. 2008. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(3):581–7.CrossRefGoogle Scholar
  152. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. 2002. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8:3584–91.PubMedGoogle Scholar
  153. McIntyre JF, Smith-Sorensen B, Friend SH, Kassel, J, et al. 1994. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 12:925–30.PubMedGoogle Scholar
  154. Mendoza S, Konishi T, Miller CW. 1998. Integration of SV40 in human osteosarcoma DNA. Oncogene 17:2457–2462.PubMedCrossRefGoogle Scholar
  155. Meyers PA, Gorlick R. 1997. Osteosarcoma. Pediatr Clin North Am 44:973–89.PubMedCrossRefGoogle Scholar
  156. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. 2005. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–11.PubMedCrossRefGoogle Scholar
  157. Miller AD, Curran T, Verma IM. 1984. c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell 36:51–60.PubMedCrossRefGoogle Scholar
  158. Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, et al. 2002. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol. 2:25–38.PubMedCrossRefGoogle Scholar
  159. Muggia FM. 2001. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 3:156–62.PubMedCrossRefGoogle Scholar
  160. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. 1990. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863–7.PubMedCrossRefGoogle Scholar
  161. Nellissery MJ, Padalecki SS, Brkanac Z, Singer FR, Roodman GD, Unni KK, Leach RJ, Hansen MF. 1998. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 63:817–24.PubMedCrossRefGoogle Scholar
  162. Nevins JR. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424–429.PubMedCrossRefGoogle Scholar
  163. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. 1998. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153(1):159–63.PubMedCrossRefGoogle Scholar
  164. Nishijo K, Nakayama T, Aoyama T, Okamoto T, Ishibe T, Yasura K, Shima Y, Shibata KR, Tsuboyama T, Nakamura T, Toguchida J. 2004. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 111:367–372.PubMedCrossRefGoogle Scholar
  165. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M. 2000. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sties in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31:709–16.PubMedCrossRefGoogle Scholar
  166. Ohta S, Hiraki Y, Shigeno C, Suzuki F, Kasai R, Ikeda T, Kohno H, Lee K, Kikuchi H, Konishi J, et al. 1992. Bone morphogenetic proteins (BMP-2 and BMP-3) induce the late phase expression of the proto-oncogene c-fos in murine osteoblastic MC3T3-E1 cells. FEBS Lett. 314:356–360.PubMedCrossRefGoogle Scholar
  167. O’Keefe RJ, Guise TA. 2003. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res 415(Suppl):S100–S104.PubMedCrossRefGoogle Scholar
  168. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–3.PubMedCrossRefGoogle Scholar
  169. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857–60.PubMedCrossRefGoogle Scholar
  170. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847–60.PubMedCrossRefGoogle Scholar
  171. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T. 1996. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71–78.PubMedCrossRefGoogle Scholar
  172. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. 2005. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104:2522–9.PubMedCrossRefGoogle Scholar
  173. Pakos EE, Ioannidis JPA. 2003. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma: A meta-analysis. Cancer 98:581–589.PubMedCrossRefGoogle Scholar
  174. Park YB, Kim HS, Oh JH, Lee SH. 2001. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307–310.PubMedCrossRefGoogle Scholar
  175. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M. 2005. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 11:490–497.PubMedGoogle Scholar
  176. Polakis P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837–1851.PubMedGoogle Scholar
  177. Pollak MN, Polychronakos C, Richard M. 1990. Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301–5.PubMedCrossRefGoogle Scholar
  178. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M. 1996. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63:37–50.PubMedCrossRefGoogle Scholar
  179. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000.PubMedCrossRefGoogle Scholar
  180. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. 1993. Met expression and sarcoma tumorigenecity. Cancer Res. 53:5355–60.PubMedGoogle Scholar
  181. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. 1982. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–30.PubMedCrossRefGoogle Scholar
  182. Ruther U, Komitowski D, Schubert FR, Wagner EF. 1989. C-fos expression induces bone tumors in transgenic mice. Oncogene 4:861–865.PubMedGoogle Scholar
  183. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. 2003. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63:627–635.PubMedGoogle Scholar
  184. Salasznyk RM, Klees RF, Hughlock MK, Plopper GE. 2004. ERK signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells on collagen I and vitronectin. Cell Commun Adhes 11:137–53.PubMedCrossRefGoogle Scholar
  185. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. 2004. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 22: 3790–7.PubMedCrossRefGoogle Scholar
  186. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P. 2001. Presence of telomerase activity in different musculoskeletal tumor hitotypes and correlation with aggressiveness. Int J Cancer 95:156–161.PubMedCrossRefGoogle Scholar
  187. Schwartz CL, Gorlick R, Teot LA, Grier HE, Krailo M, Meyers PA. 2000. A prospective study of p-glycoprotein (P-GP) expression in newly diagnosed non-metastatic osteosarcoma: An intergroup study of the Children’s Cancer Group and the Pediatric Oncology Group. Proc Am Soc Clin Oncol. 19:587a.Google Scholar
  188. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P. 2007. Mulitple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol. 25:2057–2062.PubMedCrossRefGoogle Scholar
  189. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, Manara MC, Comoglio PM, Ferracini R. 1996. Expression of Met/Hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149:1209–19.PubMedGoogle Scholar
  190. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al. 2004. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer 41:1349–61.CrossRefGoogle Scholar
  191. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. 2005. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65:3868–76.PubMedCrossRefGoogle Scholar
  192. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, and Andrulis IL. 1995. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res. 55:129–134.PubMedGoogle Scholar
  193. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. 2003. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 21:536–542.PubMedCrossRefGoogle Scholar
  194. Siddiqui R, Onel K, Facio F, Nafa K, Diaz LR, Kauff N, Huang H, Robson M, Ellis N, Offit K. 2005. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer 4:177–181.PubMedCrossRefGoogle Scholar
  195. Skubitz KM. 2003. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 21:167–76.PubMedCrossRefGoogle Scholar
  196. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. 2005. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 8:525–32.PubMedCrossRefGoogle Scholar
  197. Stock C, Kager L, Fink FM, Gadner H, Ambros PF. 2000. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 28:329–336.PubMedCrossRefGoogle Scholar
  198. Sulzbacher I, Traxler M, Mosberger I, Lang S, and Chott A. 2000. Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol. 13:632–637.PubMedCrossRefGoogle Scholar
  199. Sulzbacher I, Birner P, Trieb K, Muhlbauer M, Lang S, and Chott A. 2001. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol. 25:1520–1527.PubMedCrossRefGoogle Scholar
  200. Taichman RS, Cooper C, Keller ET, Penta KJ, Taichman NS, McCauley LK. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62:1832–1837.PubMedGoogle Scholar
  201. Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ. 2003. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Res. 63:364–74.PubMedGoogle Scholar
  202. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. 2002. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res. 8:788–793.PubMedGoogle Scholar
  203. Thomas JE, Venugopalan M, Galvin R, Wang Y, Bokoch GM, Vlahos CJ. 1997. Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase. J Cell Biochem. 64:182–95.PubMedCrossRefGoogle Scholar
  204. Toguchida J, Ishizaki K, Sasaki MS, Ikenaga M, Sugimoto M, Kotoura Y et al. 1988. Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Caner Res. 48:3939–3943.Google Scholar
  205. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. 2007. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 25:371–9.PubMedCrossRefGoogle Scholar
  206. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M. 2004. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing’s sarcomas and osteosarcomas. Genes Chromosomes Cancer 41:155–62.PubMedCrossRefGoogle Scholar
  207. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. 2003. Absence of telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759–1763.PubMedGoogle Scholar
  208. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–21.PubMedCrossRefGoogle Scholar
  209. Van BC, van SF, Curran T, Muller R, Verma IM. 1983. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 32:1241–1255.CrossRefGoogle Scholar
  210. Van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJM. 2004. Overexpression through amplification of genes in chromosome region 17q11.2-p12 in high-grade osteosarcoma. Cancer Genet Cytogenet. 152:8–14.PubMedCrossRefGoogle Scholar
  211. Van Dartel M, Hulsebos TJM. 2004. Amplification and overexpression of genes in 17p11.2-p12 in osteosarcoma. Cancer Genet Cytogenet. 153:77–80.PubMedCrossRefGoogle Scholar
  212. Vilella-Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem. 1999 Feb 12;274(7):4266–72.PubMedCrossRefGoogle Scholar
  213. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y et al. 1994. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 54:3042–3048.PubMedGoogle Scholar
  214. Wan X, Mendoza A, Khanna C, Helman LJ. 2005. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65:2406–11.PubMedCrossRefGoogle Scholar
  215. Wang LL, Levy ML, Lewis RA, Chintagumpala MM, Lev D, Rogers M, Plon SE. 2001. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 102:11–17.PubMedCrossRefGoogle Scholar
  216. Wang LL, Gannavarapu A, Kozinetz CA, Levy ML, Lewis RA, Chintagumpala MM, Ruiz-Maldanado R, Contreras-Ruiz J, Cunniff C, Erickson RP, Lev D, Rogers M, Zackai EH, Plon SE. 2003. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 95:669–674.PubMedCrossRefGoogle Scholar
  217. Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE. 1995. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55:6244–51.PubMedGoogle Scholar
  218. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, et al. 1999a. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80:199–204.PubMedCrossRefGoogle Scholar
  219. Wei G, Gorlick R, Ladanyi M, Meyers P, Huvos AG, Bertino JR, Healey JH. 1999b. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res. 365:175–183.CrossRefGoogle Scholar
  220. Weiner LM, Adams GP. 2000. New approaches to antibody therapy. Oncogene 19:6144–6151.PubMedCrossRefGoogle Scholar
  221. Weiss KR, Cooper GM, Jadlowiec JA, McGough RL, Huard J. 2006. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 450:111–177.PubMedCrossRefGoogle Scholar
  222. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G, Greco MA. 2007. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Human Pathol 38:1184–91.CrossRefGoogle Scholar
  223. Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, et al. 2006. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol. 28:261–9.PubMedGoogle Scholar
  224. Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stoval M, et al. 1997. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 278:1262–1267.PubMedCrossRefGoogle Scholar
  225. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D. 1990. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5:989–1000.PubMedGoogle Scholar
  226. Wunder JS, Bell RS, Wold L, Adrulis IL. 1993. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Othopaed Res 11:396–403.CrossRefGoogle Scholar
  227. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL. 2000. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685–2694.PubMedGoogle Scholar
  228. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, et al. 2001. Evaluation of the role of RANK and OPG genes in Paget’s disease of bone. Bone 28:104–7.PubMedCrossRefGoogle Scholar
  229. Yamamoto O, Wda T, Takahashi M, Yamawaki S, Ishii S. 2000. Prognostic value of P-glycoprotein expression in bone and soft-tissue sarcoma. Int J Clin Oncol. 5:164–170.CrossRefGoogle Scholar
  230. Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R, et al. 2007a. Over-expression of parathyroid hormone type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 121(5):943–54.PubMedCrossRefGoogle Scholar
  231. Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, et al. 2003. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res. 9:837–44.PubMedGoogle Scholar
  232. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, et al. 2007b. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res. 13:2557–67.PubMedCrossRefGoogle Scholar
  233. Yoshikawa H, Takaoka K, Masuhara K, Ono K, Sakamoto Y. 1988. Prognostic significance of bone morphogenetic activity in osteosarcoma tissue. Cancer 61:569–573.PubMedCrossRefGoogle Scholar
  234. Yu W, Chen Z, Zhang J, Zhang L, Ke H, Huang L, Peng Y, Zhang X, Li S, Lahn BT, Xiang AP. 2008. Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem 310(1–2):11–8.CrossRefGoogle Scholar
  235. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. 2003. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 25:27–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Pediatrics, Pediatric Hematology/OncologyThe Children’s Hospital at Montefiore and the Albert Einstein College of MedicineBronxUSA

Personalised recommendations